POLYCLONAL ANTIBODIES TO DOMAIN B-FREE RECOMBINANT ANTI-HEMOPHILIC FACTOR VIII: PRODUCTION, CHARACTERIZATION AND POSSIBLE BIOMEDICAL APPLICATIONS by Tykhomyrov, A. et al.
111 
 
2. Зинов, В.Г. Биосенсерные технологии: мировые драйверы развития направления / В. Г. Зи-
нов, О. В. Черченко // Экономика науки. – 2016. – Т. 2, № 1. – Р. 46-56. 
3. Scognamiglio, V. Nanotechnology in glucose monitoring: Advances and challenges in the last 10 
years / V. Scognamiglio // Biosensors and Bioelectronics. – 2013. – Vol. 47. – P. 12-25. 
4. Семашко, Т.В. Некоторые аспекты применения глюкозооксидаз Penicillium adametzii и 
Penicillium funiculosum / Т. В. Семашко, Р. В. Михайлова // Перспективные ферментные препараты 
и биотехнологические процессы в технологиях продуктов питания и кормов : сб. ст. /  Под ред. 





POLYCLONAL ANTIBODIES TO DOMAIN B-FREE RECOMBINANT  
ANTI-HEMOPHILIC FACTOR VIII: PRODUCTION, CHARACTERIZATION AND 
POSSIBLE BIOMEDICAL APPLICATIONS 
 
1
TYKHOMYROV Artem, PhD, Senior Researcher 
2,3
NEDZVETSKY Victor, Dr. Sci., Professor 
4
SHEMET Sergiy, Research Assistant 
3AĞCA Can Ali, PhD, Senior Researcher 
1
Palladin Institute of Biochemistry of NAS of Ukraine, Enzyme Chemistry & Biochemistry Dept.,  
Kyiv, Ukraine 
2
Dnipro National University, Dept. Biophysics & Biochemistry, Dnipro, Ukraine 
3Bingöl University, Dept. Molecular Biology & Genetics, Bingöl, Turkey 
4
Ukrainian Hemophilia Association, Dnipro Regional Chapter, Ukraine 
 
Introduction. Factor VIII (FVIII, anti-hemophilic factor) is an essential blood-clotting protein. FVIII gene 
mutations result in hemophilia A. The mature FVIII protein is a single polypeptide with Mm of 320 kDa 
containing three different domains (A1, A2, A3, B, C1, and C2) (Fig. 1, A). B domain does not affect FVIII 
activity in the process of blood coagulation, and B domain-deleted natural or recombinant FVIII heterodimers 
show significant activity. 
 
 
Fig. 1. Schematic structure of the full-length FVIII molecule (A) and its B-domain truncated form (moroctocog 
alpha) (B) [1]. 
 
Both plasma-derived FVIII concentrates and recombinant FVIII can be given to hemophiliac patients to 
restore hemostasis. Although various techniques for further concentrating and purifying the coagulation factors 
from donor plasma have been introduced, the problem of control of the quantity and quality of plasma-derived 
FVIII products has not been fully resolved. In screening tests during the manufacturing process immunoassays 
are used to quantify or detect the target antigen related to the disease in patient’s blood. Quantitative analysis 
based on the use of highly specific antibodies to FVIII is required in order to distinguish factor deficiency from 
factor inhibition or defects. The use of recombinant immunogenic proteins that are maximally structurally and 
immunologically analogous to native target molecules is considered to be state-of-the-art industrial 
antigen/antibody manufacturing. Moroctocog alpha, which is also referred to as BDDrFVIII (B domain 
deleted rFVIII), represents a family of third-generation FVIII products, which are free of vWF and other 
protein impurities. Moroctocog alpha is a glycoprotein with an approximate Mm of 170 kDa consisting of 1438 
amino acid residues and has functional characteristics comparable to those of endogenous FVIII [2]. In the 







specifically recognizing human native FVIII. Also, we describe main immunochemical characteristics of these 
antibodies and highlight their potential biomedical applications. 
Materials and methods. ReFacto
®
 AF (Wyeth Farma S.A., Madrid, Spain) containing 250 IU moroctocog 
alpha was used as immunogen. Commercially-available plasma-derived FVIII concentrates were used in this 
study as sources of FVIII-related antigens for immunochemical assays. Male New Zealand rabbits were 
immunized intracutaneously with antigen in two regimes: 1) BDDrFVIII (100 µg) as a suspension with 
complete Freund’s adjuvant followed by repeating boost with the half-dose of antigen emulgated with 
incomplete Freund’s adjuvant; 2) BDDrFVIII (50 µg) entrapped in 10% polyacrilamide gel (PAAG) after 
electrophoretic separation with the repeating boost with the half-dose of antigen as a PAAG suspension. Blood 
from the rabbits of the both groups was taken on 5-th, 7-th, 9-th, and 11-th days after the last antigen boost. At 
each time point, equal volumes of sera from each of the rabbits were analyzed by ELISA for antigen titers, 
using non-immune sera as a negative control. Electrophoretically homogenous IgG fraction was purified by 
affine chromatography with the use of Protein A-sepharose, and titers were measured by ELISA. Samples of 
moroctocog alpha, plasma-derived FVIII concentrates, human plasma from healthy donors and hemophilic 
volunteers, and human platelet lysates were used as sources of the FVIII-related antigens in immunoblotting. 
FVIII-specific IgG was used for FVIII-producing human umbilical vein endothelial cells (HUVECs) 
immunostaining followed by visualization with the use of LSM510 confocal laser scanning microscope (Zeiss, 
Jena, Germany).  
Results and discussion. Serological analysis (ELISA) of immune sera indicates that rabbits injected with 
PAAG-immobilized BDDrFVIII had 4-fold higher antibody titers than did the rabbits immunized in 
accordance with conventional procedure (1/12000 and 1/3000, respectively). As seen in Fig. 2, ELISA data 
indicates that rabbits injected with PAAG-immobilized BDDrFVIII had higher antibody titers compared to the 
rabbits immunized in accordance with conventional procedure. Evaluation of the purified IgG titer showed the 
significant difference between the signal from immune IgG and non-specific control threshold baseline at the 
minimal IgG concentration of ~ 50 ng per well.  
 
 
Fig. 2. ELISA absorbance profiles of specific IgG purified from serum of rabbits injected with PAAG-
encapsulated antigen or BDDrFVIII in the form of emulsion with Freund’s adjuvant. * - P < 0.05 
 
Antisera taken from both groups of rabbits reacted with the moroctocog alpha, which they produced against 
(170 kDa), FVIII-related polypeptides in both plasma-derived concentrates and human serum (Fig. 3, A). With 
that, antisera of rabbits immunized with PAAG-immobilized BDDrFVIII appeared to recognize intact native 
FVIII molecule (320 kDa) in the samples of commercial FVIII concentrates as well as whole human serum. 
However, antisera obtained from conventionally immunized rabbits were not capable of such detection. 
Immunoblotting with the use of purified IgG as the primary antibodies showed the densities of 
immunostaining of the major polypeptide 320 kDa as well as FVIII-related polypeptides with the lower 
molecular masses to be much lesser abundant in the samples of hemophilia A persons than in healthy controls 
(Fig. 3, B). IgG purified from PAAG-BDDrFVIII-injected rabbits were able to recognize FVIII-related 









Fig. 3. Immunoblotting of FVIII-related antigens with the use of immune sera (A) or specific IgG (B) as 
primary antibodies (A: 1 – moroctocog alpha – 15 μg protein; 2 – BioClot A – 25 μg; 3 – Octanate – 25 μg; 4 – 
serum of a healthy donor – 100 μg; B: 1– healthy volunteer 1; 2 – healthy volunteer 2; 3 – person with hemophilia 
A 1; 4 – person with hemophilia A 2; 5 – platelet lysate 1; 6 – platelet lysate 2). 
 
There is uncertainty about the site of FVIII synthesis, however it has been postulated that endothelial cells 
are generally responsible for FVIII production [3]. According to this, we performed immunofluorescence 
assay of HUVECs as potential FVIII producers. Fluorescence microscopy confirmed the specific binding of 
anti-FVIII antibodies with HUVECs, but not glioblastoma cells, which were used as a negative control (Fig. 
4). 
 
Fig. 4. FVIII immunofluorescence assay of human umbilical vein endothelial cells (HUVECs) (A)  (green – 
FVIII; blue – nuclear staining with Hoechst-33342). Content of immune Ig G – 20 μg/mL. B – glioblastoma U373 
cell line (negative control), inset: immunostaining for GFAP, the specific marker of glial cells). 
 
Conclusions. An optimized procedure for the production of polyclonal antibodies against FVIII with the 
use of PAAG-encapsulated BDDrFVIII (moroctocog alpha) was proposed and successfully validated. Human 
recombinant B-domainless FVIII (moroctocog alpha) appeared to be suitable for the production of highly 
specific and affine polyclonal antibodies, capable of recognizing of native whole FVIII molecule as well 
as FVIII-related truncated polypeptides. The antibodies produced can be applied for the development of 
novel protocols of highly sensitive and specific immunoassay approaches for FVIII detection in blood and 
serum-derived concentrates and further clarifying of FVIII intracellular expression and localization. 
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